The TGA has approved CSL Behring's HIZENTRA for maintenance therapy to treat chronic inflammatory demyelinating polyneuropathy (CIDP).

Melbourne-based Race Oncology (ASX:RAC) has executed an agreement with Washington DC–based advisory firm, NSF Health Sciences, to facilitate its regulatory filing in the US for leukaemia drug Bisantrene.

Sydney-based Cellmid (ASX:CDY) has announced positive efficacy results from its lead anti-midkine antibody, CAB102, in the rare kidney disease, FSGS.

Research Australia’s annual survey of views on health and medical research, Australia Speaks!, shows Australians continue to place improving hospitals and healthcare as the number one spending priority for the Australian Government - ahead of infrastructure, education standards and employment opportunities.

Industry minister Karen Andrews says investment in nine companies by the CSIRO venture fund has so far created 100 jobs.

Fast-tracking technologies through early proof-of-concept and feasibility stages is a key aim of Burnet Institute's new initiative, the Quick Development of Solutions Lab (qDOS Lab).

Health minister Greg Hunt says he is reviewing the impact of recent changes that cut the TGA orphan drug designation to six months.